TABLE 3.
Strain | Source of isolate | HHL productiona | OHL productiona | DHL productiona | Presence of bviIR genesb | Expression of bviI | Expression of bviRg | Presence of 7349 and 7350h |
---|---|---|---|---|---|---|---|---|
PC259 | Clinical | + | + | + | + | +c/−d,e | + | − |
FC466 | Clinical | (+) | (+) | − | + | −c,d,e | (+) | + |
FC441 | Clinical | + | + | − | + | −c,d,e | (+) | + |
C2822 | Clinical | + | + | − | + | −c,e | (+) | − |
FC369T | Environmental | + | + | + | + | +c,d,f | ND | + |
DBO1 | Environmental | + | + | + | + | +d,f | ND | + |
G4 | Environmental | + | + | + | + | +c,d,f | + | + |
Production of AHLs was determined by AHL-TLC bioassays using A. tumefaciens A136(pCF218)(pCF372) as the reporter strain.
The presence of the bviI and bviR genes was determined by PCR.
The expression of bviI was assessed by RT-PCR.
The expression of bviI was analyzed by transcriptional analysis of bviI-luxCDABE fusion constructs (pRM455, pRM465, pRM475, pRM485, pRM495, pRM415) in their respective host backgrounds.
The expression of bviIG4 was analyzed by transcriptional analysis of the bviIG4-luxCDABE fusion construct (pRM465).
The expression of bviIPC259 was analyzed by transcriptional analysis of the bviIPC259-luxCDABE fusion construct (pRM465).
The expression of bviR was assessed by RT-PCR with primers internal to bviR.
The presence of the 7349 and 7350 genes was determined by PCR.
+, positive; (+), weakly positive; −, negative; ND, not determined.